Results
1 -
7 of
7Peng Wu and Yongzhou Hu.
Small molecules targeting phosphoinositide 3-kinases, Med. Chem. Commun., 2012, 3, 1337. Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or lymphoma, Cancer Chemotherapy and Pharmacology PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancer, Journal of Neuro-Oncology Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models, Tumor Biology The phosphatidylinositol-3 kinase/mTOR pathway: new agents, Breast Cancer Research Phosphoinositide 3-kinase (PI3K); protein kinase CK2, Science-Business eXchange